Novel Oral Anticoagulants at 10: An Assessment of their Safety and Contemporary Use in Atrial Fibrillation

Published: 04 March 2021

  • Likes:

    Heart Icon 2
  • episode_image
    13m 16s
    Part 1 Jan Steffel John Eikelboom, Ken Okumura, Jan Steffel, Stefan H Hohnloser
Average (ratings)
No ratings
Your rating

Overview

In this virtual roundtable, our expert panel reflect on the clinical trials and real world data supporting the use of NOACs in atrial fibrillation – almost ten years since they entered the clinic.

Moderated by Prof John Eikelboom, the panel offer their analyses via a series of presentations and discussions covering a range of topics, with a special focus on their use in Japan.

This activity has been supported via an educational grant from Boehringer Ingelheim

Learning Objectives

  • Identify which individuals with atrial fibrillation should be initiated on NOAC therapy without delay
  • Interpret safety and cardiovascular data from RCTs in the context of real-world experience
  • Select appropriate treatment strategies with NOACs in atrial fibrillation patients in need of further ablation or intervention
  • Review the reversal options open to individuals experiencing a bleeding event whilst on treatment with a NOAC

Target Audience

  • Cardiologists
  • Interventional Cardiologists

More from this programme

Part 1

When to Initiate a NOAC and Patient Suitability (data presentation)

An overview of current guidelines
1 session
Jan Steffel Watch now

Part 2

Overview of Safety and Cardiovascular Data

a. Safety and cardiovascular data from RCTs b. Real-world and meta-analyses
1 session
Stefan H Hohnloser Watch now

Part 3

Dealing with Complications:

Major bleeding events and reversal
1 session
Jan Steffel Watch now

Part 4

Discussion on Safety Rates and Patient Suitability (Panel Discussion Session)

Panel recommendations of NOAC choice according to different patient populations
1 session
Panel discussion moderated by John Eikelboom Watch now

Part 5

NOAC Use with Ablation and Intervention

a. Guideline recommendations and current trends b. Use of NOACs with ablation in Japan: clinical data
1 session
Ken Okumura Watch now

Part 6

Discussion on the Current Use of NOACs in Japan

a. Use in elderly/very old pts b. Under-dosing of NOACs c. Current unmet needs
1 session
Panel Discussion Moderated by John Eikelboom Watch now

Faculty Biographies

Jan Steffel

Jan Steffel

Professor of Cardiology

Professor Jan Steffel is a cardiologist based in Zurich, Switzerland, where he serves as Senior Consultant in Electrophysiology and Cardiac Devices at the Hirslanden Clinic and Professor of Cardiology at the University of Zurich. He is widely recognised for his expertise in cardiac rhythm disorders and device-based therapies and combines a high-volume clinical practice with academic research and education at an international level.

 

Academic History

Professor Steffel is board-certified in Internal Medicine and Cardiology and holds advanced professional certifications in Invasive Electrophysiology and Cardiac Devices from both the European Heart Rhythm Association (EHRA) and the International Board of Heart Rhythm Examiners (IBHRE). His academic output includes more than 150 publications in national and international peer-reviewed journals. He has also co-authored two textbooks focusing on General Cardiology and Anticoagulation, contributing to postgraduate…

View full profile